Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic markers of bevacizumab-induced hypertension.

Angiogenesis - 1 Jul 2014

Lambrechts Diether, Moisse Matthieu, Delmar Paul, Miles David W, Leighl Natasha, Escudier Bernard, Van Cutsem Eric, Bansal Aruna T, Carmeliet Peter, Scherer Stefan J, de Haas Sanne, Pallaud Celine

Abstract excerpt

PURPOSE: There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We combined biomarker data from six phase III trials of bevacizumab to assess whether genetic variation in vascular endothelial growth factor-A (VEGF-A) pathway or hypertension-related genes are associated with bevacizumab-induced hypertension. EXPERIMENTAL DESIGN: Germline DNA was available from 1,631...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Demography

Share to Endpoint Determination

Share to Hypertension

Share to Incidence

Share to Placebos

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 24558090
DOI: 10.1007/s10456-014-9424-7

Genes

KDR
EGF
EGLN3
FLT1
WNK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic markers of bevacizumab-induced hypertension.PMID 24558090Read ↗

Genetic predisposition to bevacizumab-induced hypertension.Semantic proximity Read ↗

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Semantic proximity Read ↗

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.Semantic proximity Read ↗

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Semantic proximity Read ↗

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Semantic proximity Read ↗

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).Semantic proximity Read ↗

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.Semantic proximity Read ↗

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Semantic proximity Read ↗

Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.Semantic proximity Read ↗

The role of vascular endothelial growth factor genetic variability in cancer.Semantic proximity Read ↗

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.Semantic proximity Read ↗

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.